Tempus AI Q1 2026: Revenue Beats Expectations, But Stock Drops on Wider Losses
Tempus AI revenue rose 36% to $348M, but losses widened. Stock fell ~7% after weaker profit and cautious outlook.
/ 57 items
#XY Earnings Movers↓
Summit Therapeutics Drops 21%: The “Continue” News That Spooked Investors
Summit stock fell after its cancer drug update was just “keep going,” not the big win investors hoped for.
Moderna Beats Q1 2026 Revenue Estimates as International Sales Surge, Stock Jumps
Moderna beat Q1 revenue on strong overseas COVID vaccine sales, revenue $389M, smaller US demand, reported a per-share loss.
Eli Lilly Crushes Q1 Earnings and Raises 2026 Profit Forecast as Zepbound & Mounjaro Sales Explode
Eli Lilly raised profit outlook thanks to strong Zepbound & Mounjaro sales; revenue and earnings beat expectations, stock rose.
Teva Beats Q1 2026 Forecasts as AUSTEDO & UZEDY Surge — Acquires Emalex for $700M Tourette Drug
Teva buys Emalex for $700M to add a new Tourette drug. Strong sales growth led by key medicines; generics weaker but outlook solid.
Humana Beats Q1 2026 Earnings Expectations, Reaffirms Full-Year Adjusted Profit Guidance
Humana beat Q1 2026 expectations, revenue rose, Medicare membership grew, outlook steady but GAAP cut due to lower ratings.